Temporal analysis of remote electric neuromodulation for the prevention of migraine.

Blumenfeld, Andrew M; Rabany, Liron; Ironi, Alon; Stark-Inbar, Alit; Harris, Dagan; Halker Singh, Rashmi B; Harriott, Andrea M

Blumenfeld, Andrew M; Rabany, Liron; Ironi, Alon; Stark-Inbar, Alit; Harris, Dagan; Halker Singh, Rashmi B; Harriott, Andrea M.

Afiliação

Blumenfeld AM; The Los Angeles Headache Center, Los Angeles, CA 90067, USA.
Rabany L; San Diego Headache Center, San Diego, CA 92111, USA.
Ironi A; Theranica Bio-Electronics, Netnaya, 4250438, Israel.
Stark-Inbar A; Theranica Bio-Electronics, Netnaya, 4250438, Israel.
Harris D; Theranica Bio-Electronics, Netnaya, 4250438, Israel.
Halker Singh RB; Theranica Bio-Electronics, Netnaya, 4250438, Israel.
Harriott AM; Mayo Clinic, Scottsdale, AZ 85259, USA.

Pain Manag ; 13(8): 425-432, 2023 Aug.

Article em En | MEDLINE | ID: mdl-37615080

ABSTRACT

ABSTRACT

Aim:

To evaluate the onset, magnitude and persistence of efficacy of remote electrical neuromodulation (REN) compared with placebo for the preventive treatment of migraine. Materials &

methods:

Analysis was conducted on data from a prospective, double-blind, placebo-controlled clinical trial, which assessed the efficacy of REN for the prevention of migraine. The number of monthly migraine days (MMD) per group was calculated in 2-week intervals and compared between the groups.

Results:

Differences between the active (N = 95) and placebo (N = 84) groups reached significance at 2 weeks therapeutic gain 0.84 MMD; p = 0.036. 4 weeks gain 1.59 MMD; p = 0.025, 6 weeks gain 2.27 MMD; p < 0.001, 8 weeks gain 2.68 MMD; p < 0.001.